Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.

Abstract: The present invention relates to personal care compositions comprising malodor reduction compositions and methods of making and using such personal care compositions. Such personal care compositions comprising the malodor control technologies disclosed herein provide malodor control without leaving an undesirable scent and when perfume is used to scent such compositions, such scent is not unduly altered by the malodor control technology.

Abstract: The present invention relates to personal care compositions comprising malodor reduction compositions and methods of making and using such personal care compositions. Such personal care compositions comprising the malodor control technologies disclosed herein provide malodor control without leaving an undesireable scent and when perfume is used to scent such compositions, such scent is not unduely altered by the malodor control technology.

Abstract: The invention provides for novel thermo-responsive polymers and compositions comprising the same. In some embodiments, the polymers are water soluble, pH-degradable and have tunable lower critical solution temperatures. Other aspects of the invention include micelles and gels comprising the thermo-responsive polymers and derivatives thereof, as well as methods of delivering therapeutic agents comprising administering a biodegradable gel or micelle comprising a polyacetal compound cross-linked with a linker.

Abstract: Compositions of alkaline salts and metabolic acid inducers and methods of use thereof are provided. The disclosed compositions may be used for stimulating vagal nerve efferent pathways, treating or preventing an inflammatory response or an autoimmune disorder, inhibiting or reducing one or more inflammatory M1 macrophages and/or one or more inflammatory neutrophils in the blood, promoting polarization of macrophages from a pro-inflammatory M1 state to an anti-inflammatory M2 state, and treating or preventing cardiovascular disease or metabolic disorders.

Abstract: Described herein are unit oral dose compositions that reduce the severity of heartburn and/or the risk of the occurrence of heartburn in a human in need of taking naproxen sodium for the OTC treatment of acute pain wherein the human is not experiencing heartburn prior to the oral administration of the unit oral dose composition comprising orally administering to the human of a unit oral dose composition comprising (i) naproxen sodium at a dosage from about 100 mg to about 440 mg per unit oral dose composition and (ii) famotidine at a dosage from about 3 mg to about 20 mg per unit oral dose composition, wherein the dissolution rate of famotidine in the unit oral dose composition in said human at a specified time within 45 minutes of administration of said unit oral dose composition to said human is greater than the dissolution rate of naproxen sodium in the unit oral dose composition in said human at the same specified time.

Abstract: Embodiments are directed to secnidazole formulations and the use of a secnidazole formulation for the treatment of trichomoniasis in a subject in need thereof.

Abstract: The present invention provides methods of assessing suitability of a pharmaceutical composition for medical use. The pharmaceutical composition comprises nanoparticles comprising rapamycin coated with albumin and a non-nanoparticle portion comprising albumin and rapamycin.

Abstract: The invention provides a liquid-dispersible powder comprising nanoscale grains of matrix embedded with one or more isolated nanoparticles and a composition for the magnetic nanoparticle hyperthermia (MNH) treatment of tumours comprising nanoscale grains of matrix material containing one or more isolated nanoparticles. The invention also provides a method of production of a liquid-dispersible powder described herein, the method comprising the steps of providing nanoparticles prepared under ultra-high vacuum (UHV) gas phase conditions; co-depositing the nanoparticles within a matrix material under UHV gas phase conditions; and grinding the film to a fine powder comprising grains of groups of matrix material isolated nanoparticles.

Abstract: Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.

Abstract: The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition for oral administration comprising an (a) inert substrate and a (b) mixture comprising a non-bile acid farnesoid X receptor (FXR) agonist, such as 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder. The present invention also relates to a process for preparing said pharmaceutical composition for oral administration; and to the use of said pharmaceutical composition in the manufacture of a medicament.

Abstract: The present subject matter includes novel chemical formulations having antimicrobial, antifungal, antiseptic, and related effect in a wide range of applications for treating or preventing infections as well as treating various surfaces that may become tainted with infectants. In some embodiments, the formulation includes isoamyl hexanoates and at least one of propanoic and/or isobutyric acid.

Abstract: The present invention includes novel chemical formulations having antimicrobial activity and their methods of use thereof. In some embodiments, the formulation further comprises at least one fungus.

Abstract: The present disclosure relates generally to compositions and methods for improving gastrointestinal absorption function and correct deficiencies by preserving intestinal epithelial absorptive function. In particular, the compositions and methods for useful for improving gastrointestinal absorption of electrolytes.

Abstract: Described herein are compositions and methods for the treatment and prevention of cognitive decline in subjects. Generally, among other potential components, the compositions comprise Centella asiatica or an extract thereof; ?-tocopherol or a derivative thereof; Ginseng or an extract thereof; a selenium compound, and ?-lipoic acid. Also provided are methods of making such compositions.

Abstract: Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease.

Abstract: Presented herein are compositions comprising L-serine, or a precursor, derivative or conjugate thereof, and a non-toxic metal, such as zinc. Compositions disclosed herein can be used for the prevention and treatment of neurodegenerative diseases, or related symptoms thereof.

Abstract: An oral, solid dosage form comprising a mixture of compound of formula I and a fusible polymeric carrier; and optionally pharmaceutically acceptable excipients, wherein the mixture is an amorphous dispersion.

Abstract: An emulsion comprising a continuous aqueous phase and a dispersed fatty phase in the form of drops, or conversely, wherein the drops comprise a shell formed of at least one anionic polymer comprising at least one carboxylic acid function and at least one cationic polymer comprising at least two amine functional groups, wherein the quantity of amine functional groups provided by the cationic polymer in the fatty phase is between 0.2 ?mol and 10.5 ?mol per gram of fatty phase.

Abstract: A hair treatment composition comprising (a) from 0.01 to 10 wt % of surfactant in a solvent, by weight of the total composition, and (b) a mixture of amino acids, wherein the mixture of amino acids comprises glutamic acid, alanine and proline gives damage repair benefits to chemically damaged hair.